{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:14:44Z","timestamp":1778220884049,"version":"3.51.4"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503668, 82473560"],"award-info":[{"award-number":["82503668, 82473560"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) have transformed the management of advanced lung cancer, yet most patients experience primary resistance, hyperprogressive disease (HPD), or clinically significant immune-related adverse events (irAEs). Multi-omics technologies now enable integrated interrogation of tumor, microenvironmental, host, and clinical determinants of these divergent outcomes. In this review, we first discuss the biological and clinical foundations of PD-1\/PD-L1 blockade in non-small cell and small cell lung cancer, and summarize the spectrum of resistance, HPD, and irAEs observed in trials and real-world practice. We then describe multi-omics study frameworks that connect genomics, transcriptomics, epigenomics, proteomics, metabolomics, radiomics, and microbiome profiling with these outcome phenotypes. Building on this foundation, we synthesize evidence for composite biomarkers of primary and acquired resistance, delineate emerging multi-omics signatures of HPD, and examine host- and tumor-derived multi-omics correlates of organ-specific and systemic irAEs. We further propose an efficacy\u2013risk quadrant framework to guide clinical decision-making when favorable efficacy predictors coexist with elevated risk of severe adverse outcomes, and outline a three-step approach for high-efficacy\/high-risk patients: joint probability reporting, multi-omics guided mitigation, and dynamic reassessment. Finally, we evaluate translational strategies that integrate multi-omics scores into baseline risk stratification, dynamic monitoring with attention to technical challenges such as distinguishing true progression from ctDNA pseudoprogression, and biomarker-driven trial design, while assessing the evidence level and translational readiness of candidate assays from retrospective discovery to clinical implementation. A clinical case illustrates how multi-omics can link baseline risk stratification, regimen selection, and longitudinal monitoring into a coherent action plan, while acknowledging that artificial intelligence-driven models remain investigational and real-world application still relies on clinician judgment. Collectively, this review defines how integrated multi-omics biomarkers can be leveraged to predict resistance, HPD, and immune-related toxicity, and to refine patient selection and management during PD-1\/PD-L1 therapy in lung cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1780459","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:50:57Z","timestamp":1778219457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1\/PD-L1 therapy in lung cancer: a literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Na","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Yantaishan Hospital","place":["Yantai, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyue","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Nursing and Midwifery, University of Galway","place":["Galway, Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Weifang People\u2019s Hospital, Shandong Second Medical University","place":["Weifang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxue","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglin","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica C.","family":"Hsu","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Purdue University","place":["West Lafayette, IN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujie","family":"Sui","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Yantaishan Hospital","place":["Yantai, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0043","article-title":"NCCN Guidelines\u00ae Insights: Non-small cell lung cancer, version 7.2025","volume":"23","author":"Riely","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy - are we making headway","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2025.11.021","article-title":"Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity","volume":"59","author":"Lucas","year":"2026","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/aitc202402200","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","article-title":"Targeting molecular pathways to control immune checkpoint inhibitor toxicities","volume":"46","author":"Reschke","year":"2025","journal-title":"Trends Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13046-020-01721-9","article-title":"Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know","volume":"39","author":"Camelliti","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cllc.2024.03.001","article-title":"Redefining clinical hyperprogression: the incidence, clinical implications, and risk factors of hyperprogression in non-small cell lung cancer treated with immunotherapy","volume":"25","author":"Djunadi","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104980","article-title":"Predictive models for immune checkpoint inhibitor response in cancer: a review of current approaches and future directions","volume":"216","author":"Oisakede","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2022.11.050","article-title":"A guide to multi-omics data collection and integration for translational medicine","volume":"21","author":"Athieniti","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71317","article-title":"Metabolic reprogramming in lung cancer: hallmarks, mechanisms, and targeted strategies to overcome immune resistance","volume":"14","author":"Chen","year":"2025","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-023-01139-8","article-title":"Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations","volume":"21","author":"Wu","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.20517\/cdr.2025.14","article-title":"Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation","volume":"8","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123851","article-title":"Acquired resistance to PD-1\/PD-L1 blockade in lung cancer: mechanisms and patterns of failure","volume":"12","author":"Pathak","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4197","article-title":"Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer","volume":"10","author":"Sun","year":"2021","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.20517\/cdr.2024.154","article-title":"Mechanisms of immunotherapy resistance in small cell lung cancer","volume":"7","author":"Nie","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105897","article-title":"Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 \u226550","volume":"10","author":"De Giglio","year":"2025","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2165\/11532200-000000000-00000","article-title":"Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/jitc-2022-sitc2022.0522","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1390","article-title":"Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13594","article-title":"Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Choi","year":"2020","journal-title":"Thorac Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20178124","article-title":"Multi-omics factor analysis-a framework for unsupervised integration of multi-omics data sets","volume":"14","author":"Argelaguet","year":"2018","journal-title":"Mol Syst Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jtho.2019.12.031","article-title":"Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma","volume":"182","author":"Gillette","year":"2020","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100596","article-title":"Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy","volume":"3","author":"Zhao","year":"2023","journal-title":"Cell Rep Methods"},{"key":"B46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","article-title":"Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade","volume":"43","author":"Tsai","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41419-023-05757-5","article-title":"Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12943-024-02160-2","article-title":"A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00555","article-title":"Plasma proteome-based test for first-line treatment selection in metastatic non-small cell lung cancer","volume":"8","author":"Christopoulos","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05509-7","article-title":"Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.semnuclmed.2025.11.024","article-title":"PET-CT radiomics for immunotherapy response","volume":"56","author":"Artesani","year":"2026","journal-title":"Semin Nucl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1708692","article-title":"Radiomics reveals the biological basis for non-small cell lung cancer prognostic stratification by reflecting tumor immune microenvironment heterogeneity","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41571-023-00785-8","article-title":"Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy","volume":"20","author":"Thomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2024-0038","article-title":"Intratumoral microbiota in orchestrating cancer immunotherapy response","volume":"12","author":"Zou","year":"2024","journal-title":"J Transl Int Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban","year":"2023","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1519082","article-title":"Immune-related adverse events with PD-1\/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients","volume":"16","author":"Yan","year":"2025","journal-title":"Front Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41525-022-00345-6","article-title":"Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity","volume":"7","author":"Chin","year":"2022","journal-title":"NPJ Genom Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30475-7","article-title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","volume":"21","author":"Redman","year":"2020","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112804","article-title":"Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer","volume":"28","author":"Semitekolou","year":"2025","journal-title":"iScience"},{"key":"B64","doi-asserted-by":"publisher","first-page":"q902","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Emitekolou","year":"2024","journal-title":"Bmj"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"Bmj"},{"key":"B67","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s42003-022-03243-w","article-title":"Bayesian networks elucidate complex genomic landscapes in cancer","volume":"5","author":"Angelopoulos","year":"2022","journal-title":"Commun Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.23.057893","article-title":"Causal integration of multi-omics data with prior knowledge to generate mechanistic hypotheses","volume":"17","author":"Dugourd","year":"2021","journal-title":"Mol Syst Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02706-7","article-title":"Graph machine learning for integrated multi-omics analysis","volume":"131","author":"Valous","year":"2024","journal-title":"Br J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"B73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.004","article-title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review","volume":"4","author":"Dong","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(18)30284-4","article-title":"Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis","volume":"6","author":"Duruisseaux","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123574","article-title":"Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer","volume":"12","author":"Ghini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.678753","article-title":"Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer","volume":"8","author":"Nie","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02351-7","article-title":"Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer","volume":"57","author":"Aung","year":"2025","journal-title":"Nat Genet"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1186\/s12885-020-07206-4","article-title":"Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106720","article-title":"Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients","volume":"26","author":"Gong","year":"2023","journal-title":"iScience"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01749-3","article-title":"Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature","volume":"16","author":"Yang","year":"2025","journal-title":"Discov Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01620","article-title":"CCND1 amplification contributes to immunosuppression and is associated with a poor prognosis to immune checkpoint inhibitors in solid tumors","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415802","article-title":"The educational program of macrophages toward a hyperprogressive disease-related phenotype is orchestrated by tumor-derived extracellular vesicles","volume":"23","author":"Indino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06023-8","article-title":"PD-L1 and IFN-\u03b3 modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)","volume":"23","author":"Angelicola","year":"2025","journal-title":"J Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.12.008","article-title":"Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2312628","article-title":"Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition","volume":"13","author":"Li","year":"2024","journal-title":"Oncoimmunology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001343","article-title":"Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade","volume":"8","author":"Vaidya","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10238-024-01324-0","article-title":"Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients","volume":"24","author":"Mei","year":"2024","journal-title":"Clin Exp Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad184","article-title":"Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"54","author":"Liang","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100754","article-title":"Germline human leukocyte antigen status is associated with immunotherapy-induced pneumonitis and treatment response in patients with non-small cell lung cancer with high programmed death-ligand 1 expression","volume":"6","author":"Cheung","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100868","article-title":"Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors","volume":"4","author":"Bukhari","year":"2023","journal-title":"Cell Rep Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109946","article-title":"Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer","volume":"27","author":"Gao","year":"2024","journal-title":"iScience"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111412","article-title":"Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor","volume":"127","author":"Yu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31100473","article-title":"Managing select immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"31","author":"Cheema","year":"2024","journal-title":"Curr Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-3473","article-title":"Lung Master Protocol (Lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400","volume":"21","author":"Herbst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1497300","article-title":"Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115803","article-title":"Analytical validation of the PROphet test for treatment decision-making guidance in metastatic non-small cell lung cancer","volume":"238","author":"Ben","year":"2024","journal-title":"J Pharm BioMed Anal"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1733357","article-title":"A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition","volume":"16","author":"Flatt","year":"2025","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.8080","article-title":"Integration of circulating tumor DNA and metabolic parameters on (18)F-fludeoxyglucose positron emission tomography for outcome prediction in unresectable locally advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013592","article-title":"Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC","volume":"14","author":"Onieva","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01327-y","article-title":"Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab","volume":"10","author":"Stutheit-Zhao","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00432-024-06030-8","article-title":"Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxt010","article-title":"Adaptive enrichment designs for clinical trials","volume":"14","author":"Simon","year":"2013","journal-title":"Biostatistics"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.007","article-title":"Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib","volume":"166","author":"Bauml","year":"2022","journal-title":"Lung Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PloS One"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PloS One"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04040-7","article-title":"Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic review and meta-analysis","volume":"28","author":"Tellez Castillo","year":"2026","journal-title":"Clin Transl Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1780459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:00Z","timestamp":1778219460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1780459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2026.1780459"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1780459","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1780459"}}